Acquisition momentum Gateway Genomics has a recent history of strategic acquisitions and partnerships, including its acquisition by Myriad Genetics in 2022 and prior integration with SneakPeek, suggesting ongoing opportunities for cross-sell, integration capabilities, and expanded distribution through parent company networks.

Direct-to-consumer scale With a strong DTC focus in prenatal testing and a notable consumer brand presence via SneakPeek, there are opportunities to expand consumer-facing products, bundled offerings, or loyalty programs targeting expectant families and maternal health channels.

Inc. 5000 credibility Multiple years of Inc. 5000 recognition indicate rapid growth and market credibility, making it easier to approach hospitals, clinics, and partners for co-marketing, referrals, or clinical collaborations in prenatal genetics.

Revenue visibility Current revenue range suggests a small but scalable business with room to upsell premium tests, expand regional availability, and pursue enterprise partnerships with fertility clinics, pediatric practices, and OB/GYN networks.

Technology leverage Existing tech stack and digital channels (SneakPeek platforms) imply sales opportunities around digital onboarding, telehealth integrations, and data-driven marketing partnerships to boost adoption and repeat use among families.